While shares of Teva (TEVA 2.09%) have risen a modest 9% year to date, the company is trading at low valuation compared to many of its peers in the pharmaceutical industry. Its forward P/E is significantly lower than major players like Merck, Pfizer, and Mylan, but what specific topics should investors focus on when analyzing this investment today? In the following video, analyst Max Macaluso discusses three key issues on his radar: Teva's standing in the multiple sclerosis market and competition from companies including Biogen (NASDAQ: BIIB), rumors around a possible merger, and its leadership.
S&P 500
5,970.81
+0.0%
+$0.44
DJI
42,427.74
-0.2%
-$91.90
NASDAQ
19,460.49
+0.3%
+$61.53
Bitcoin
104,867.00
-1.0%
-1,043.28
AAPL
$202.99
-0.1%
-$0.28
AMZN
$207.37
+0.8%
+$1.66
GOOG
$169.50
+1.1%
+$1.79
META
$687.21
+3.1%
+$20.36
MSFT
$464.20
+0.3%
+$1.23
NVDA
$141.94
+0.5%
+$0.72
TSLA
$333.21
-3.2%
-$11.06
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.